To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Benefits include better discrimination between risk levels. (HealthDay News) — Patient-centered pathology reports (PCPR) help patients to understand prostate cancer results better than current ...

Individual patient data (IPD) analysis of early PSA nadir in ARASENS, LATITUDE, and TITAN: Training and validation of a novel model. Assessing genomic instability (GI) by shallow whole-genome ...

If you’ve recently been diagnosed with prostate cancer, or if you’ve had a prostate biopsy to test for prostate cancer, you might have seen the term “Gleason score” or “Gleason grade” on the pathology ...

Human tissue is intricate, complex and, of course, three dimensional. But the thin slices of tissue that pathologists most often use to diagnose disease are two dimensional, offering only a limited ...

Urological malignancies, including prostate, bladder, renal, and testicular cancers, represent a major global health burden and display remarkable ...

Stage 2 prostate adenocarcinoma is localized, with a nearly 100% five-year relative survival rate. Diagnosis uses the TNM system, PSA levels, and Gleason score to determine cancer stage and risk.

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug ...

DEAR DR. ROACH: I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One blood test showed a PSA level of 13 ng/mL, and a second was ...